# Tiotropium/Salmeterol Inhalation Powder in COPD

> **NCT00668772** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 207 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium/Salmeterol
- **DRUG:** Tiotropium/Salmeterol QD + Salmeterol
- **DRUG:** Placebo
- **DRUG:** Salmeterol
- **DRUG:** Tiotropium

## Key facts

- **NCT ID:** NCT00668772
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04-15
- **Primary completion:** 2008-11-21
- **Final completion:** 2008-11-21
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00668772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00668772, "Tiotropium/Salmeterol Inhalation Powder in COPD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00668772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*